Revvity Inc. (NYSE:RVTY) Plans Quarterly Dividend of $0.07

Key Points

• Revvity declared a quarterly dividend of $0.07 per share, payable November 13 to shareholders of record October 23. The dividend annualizes to $0.28 per share, yielding approximately 0.2%.
• The dividend appears well covered, with a current payout ratio of 5.1% and an expected future payout ratio of 4.7% based on analysts’ projected earnings.
• Revvity exceeded quarterly earnings and revenue expectations, reporting $1.41 in EPS versus a $1.21 estimate and $729.69 million in revenue. Despite several positive analyst ratings, the consensus rating remains Hold, with a $124.43 average price target.

Revvity Inc. (NYSE:RVTY - Get Free Report) announced a quarterly dividend on Friday, July 31st. Shareholders of record on Friday, October 23rd will be paid a dividend of $0.07 per share on Friday, November 13th. This represents a $0.28 annualized dividend and a yield of 0.2%. The ex-dividend date of this dividend is Friday, October 23rd.

Revvity has a payout ratio of 5.1% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Revvity to earn $5.92 per share next year, which means the company should continue to be able to cover its $0.28 annual dividend with an expected future payout ratio of 4.7%.

Revvity Price Performance

Shares of NYSE RVTY opened at $158.86 on Wednesday. The company has a current ratio of 1.80, a quick ratio of 1.50 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $17.73 billion, a price-to-earnings ratio of 74.79, a price-to-earnings-growth ratio of 2.75 and a beta of 1.06. Revvity has a twelve month low of $81.22 and a twelve month high of $166.25. The business has a 50 day simple moving average of $137.99 and a 200-day simple moving average of $114.56.

Revvity (NYSE:RVTY - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $1.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.21 by $0.20. Revvity had a return on equity of 8.34% and a net margin of 8.16%. The firm had revenue of $729.69 million for the quarter, compared to analysts' expectations of $702.96 million. During the same period last year, the business posted $1.18 earnings per share. The firm's revenue for the quarter was down 1.3% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities research analysts expect that Revvity will post 5.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

RVTY has been the topic of a number of recent research reports. TD Cowen raised their price target on shares of Revvity from $130.00 to $175.00 and gave the stock a "buy" rating in a research report on Tuesday, October 13th. Sanford C. Bernstein assumed coverage on shares of Revvity in a research report on Friday, June 26th. They set a "market perform" rating and a $115.00 price objective for the company. Wall Street Zen downgraded shares of Revvity from a "buy" rating to a "hold" rating in a research report on Sunday, August 16th. Evercore reiterated an "outperform" rating on shares of Revvity in a research note on Wednesday, August 5th. Finally, Barclays raised their target price on shares of Revvity from $115.00 to $160.00 and gave the stock an "equal weight" rating in a report on Wednesday, October 7th. Five equities research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $124.43.

About Revvity

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.